Assessment of Coagulation Factor Levels in Left Ventricular Device (LVAD )Patients Following Temporary Warfarin Reversal With Four Factor Prothrombin Complex Concentrate (4F-PCC)



Status:Recruiting
Healthy:No
Age Range:18 - 80
Updated:4/17/2018
Start Date:February 7, 2018
End Date:March 31, 2020
Contact:Jean M Connors, MD
Email:jconnors@bwh.harvard.edu
Phone:617-525-9337

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Assessment of Coagulation Factor Levels in LVAD Patients Following Temporary Warfarin Reversal With 4F-PCC

Prospective assessment of vitamin K dependent coagulation factor levels after temporary
warfarin reversal in participants with left ventricular assist devices (LAVD).

Prospective evaluation of the levels of the vitamin K dependent coagulation factors 2,7,9,10,
and proteins C and S, in patients on warfarin treated with four factor prothrombin complex
concentrate (4F-PCC). Participants on vitamin K antagonists (VKA) such as warfarin have
suppressed levels that are brought to the normal range with treatment with 4F-PCC to reverse
the warfarin effect. The investigators will assess the duration of effect of 4F-PCC on these
factor levels in participants with left ventricular assist devices (VAD) requiring temporary
reversal of warfarin for invasive procedures that have a risk of bleeding. The investigators
will also assess the time to return to therapeutic INR..

Inclusion Criteria:

- LVAD on warfarin requiring temporary interruption of anticoagulation for procedures

Exclusion Criteria:

- recent thrombotic event
We found this trial at
1
site
Brigham and Women's Hosp
75 Francis street
Boston, Massachusetts 02115
(617) 732-5500
Phone: 617-525-9337
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
?
mi
from
Boston, MA
Click here to add this to my saved trials